Number 83; June 1, 2005
A Deer Animal
With permission of Graham Jeffery
This newsletter keeps you up-to-date with new articles, Web pages, and books that I have written about diabetes.
My recent contribution is:
Now we can get a GlycoMark test. It has just become available in this country. Developed by two companies in Japan, it has, however, been used there for more than a decade.
What it does best is to reflect blood glucose spikes after you eat. For people who have their diabetes under pretty good control that can be the key to doing even better.
I wrote about the GlycoMark test for my “Meter News” column in the June issue of Diabetes Health magazine. My column is also online at http://www.mendosa.com/glycomark.htm.
Research Notes:
They call the drug Muraglitazar. In Phase 3 clinicial trials just completed its results were impressive. After just 24 weeks A1C levels typically dropped considerably. Triglyceride levels dropped and HDL (good cholesterol) levels rose. The details are complex, depending on the amount of the drug, the baseline A1C level, and whether the trial was double-blind and placebo-controlled or open label. You can read further details at the BMS press release.
If and when Muraglitazar becomes available, we will have eight classes of oral drugs to chose from, all of which I list, describe, and link at http://www.mendosa.com/drugs.htm. Before 1955 insulin was our only choice. From 1955 to 1995 the only oral drug choice was a sulfonylurea. Then, in rapid succession came a biguanide (metformin or Glucophage), alpha-glucosidase inhibitors (Precose and Glyset), thiazolidinedione (Avandia and Actos), meglitinide (Prandin), an amino acid D-phenylalanine derivative (Starlix), and quite recently at incretin mimetic (Byetta or exenatide).
Book Reviews:
There doesn’t seem to be anything that people like to tell us more than what we should eat. Of course, they all have completely contradictory advice. This month two new books keep that record intact.
Beating Diabetes
The authors of Beating Diabetes have excellent credentials. David M. Nathan, M.D., is the director of the Diabetes Center at Massachusetts General Hospital and a researcher for both the Diabetes Prevention Program and the Diabetes Control and Complications Trial. The co-author (and probably the one who did most of the work on this book) is Linda M. Delahanty, the center’s chief dietitian. For good measure the dustcover makes a point of stating that the book is “from Harvard Medical School” and is “based on groundbreaking scientific studies.”
Who could resist? In broad terms I can’t fault their advice — only the way they give it. Maybe I’m jaded from reading too many diabetes books, but this one just didn’t excite me or motivate me to make any changes in my imperfect life.
The recommended lifestyle changes to treat type 2 diabetes, summarized on pages 53-4, shouldn’t be any revelation:
McGraw-Hill Trade lists this 272-page hardcover for $24.95. The ISBN is 0071438319.
The French Diet
Unlike Dr. Nathan and his co-author, he has been around the diet scene for years. And unlike them (and me) he doesn’t have the proper credentials. M. Montignac is a businessman who lost 30 pounds and lived to write about it.
I certainly don’t think that M. Montignac’s lack of academic credentials is important. But academics at least make an attempt to be accurate. M. Montignac doesn’t.
The French Diet is a low-glycemic diet — one that is certain to give the glycemic index a bad name. What irritates me most about this book — and to a certain extent his previous books — is how he plays fast and lose with glycemic index values. His list on pages 32-35 is simply wrong about the GI values of many foods (including barley and maple syrup) and lists values for many food that have never been scientifically tested (like quinoa, figs, onions, and tomatoes).
The purported “breakthrough” of this book, according to the publisher’s press release, “is in examining the net GI values of combined foods eaten as a meal.” M. Montignac calls the the “glycemic outcome.” He doesn’t even do the calculations correctly, just averaging the GI values of the foods in a meal (page 93).
In fact, this is less precise than calculating the glycemic index of a mixed meal. We’ve had this concept for years. I describe it at http://www.mendosa.com/gi.htm.
“I don’t know what he means by net GI values of foods eaten as a meal unless he’s worked out the GI of the mixed meal based on weighted GI values,” Professor Jennie Brand-Miller tells me. She is the leading glycemic index researcher. “We don’t need to do that.”
DK Publishing lists this 192-page hardcover (one-half of which is recipes) for $20. The ISBN is 075661578X.
Announcements:
Archives:
I now send out Diabetes Update once a month. Previous issues are online:
You have received this newsletter because you subscribed to it at www.mendosa.com. If someone has falsely subscribed on your behalf or if you want to stop receiving further issues of this newsletter, then please e-mail me here.
© Copyright 2005 David Mendosa. All Rights Reserved.
David Mendosa
A Writer on the Web: www.mendosa.com
E-mail: mendosa@mendosa.com
Office: 993 E. Moorhead Circle Suite 2F, Boulder, CO 80305